Isolation and characterization of degradation impurities in epirubicin hydrochloride injection
Dinesh Kumar1, Rajesh Singh Tomar, Santosh Kumar Deolia
1Analytical Laboratory-I, Dabur Research Foundation, 22 Site-IV, Sahibabad, Ghaziabad, Uttar Pradesh, India.
Abstract:
The degradation of epirubicin hydrochloride aqueous formulation has been investigated during stability study. Some unknown degradation impurities were detected and out of these, three were characterized. These degradation impurities were isolated, enriched and were subjected to mass and NMR spectral studies. Based on the spectral data these were characterized as epirubicin dimer (impurity-1), 4-(4-amino-5-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-naphthacene-2-carboxylic acid hydroxymethyl ester (impurity-3) and 4-(4-amino-5-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-naphthacene-2-carboxylic acid (impurity-4). Structure elucidations of these degradation impurities are discussed in detail. Out of these degradation impurities, epirubicin dimer (impurity-1) has been previously identified while the other two impurity-3 and impurity-4 were previously unreported.
More Related Videos
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
10:58Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
Published on: August 21, 2019
Related Concept Videos
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Production of Pharmaceuticals
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Ion-Exchange Chromatography
